Pharmacology: Pharmacokinetics: Cefuroxime axetil is absorbed from the GIT and is rapidly hydrolyzed in the intestinal mucosa and blood to cefuroxime. Absorption is enhanced in the presence of food. Peak plasma concentrations are reported about 2-3 hrs after an oral dose. It is widely distributed in the body including pleural fluid, sputum, synovial fluid and aqueous humor, but only achieves therapeutic concentrations in the CSF when the meninges are inflamed. It crosses the placenta and has been detected in breast milk. It is excreted unchanged by glomerular filtration and renal tubular secretion and high concentrations are achieved in the urine.
Cefuroxime axetil is a 2nd generation cephalosporin antibiotic used in the treatment of susceptible infections. These have included bone and joint infections, bronchitis (and other lower respiratory tract infections), gonorrhea, meningitis, otitis media, peritonitis, pharyngitis, sinusitis, skin infections (including soft tissue infections) and urinary tract infections. It is also used for surgical infection prophylaxis.
Usual oral dose for adults is 125 mg twice daily for uncomplicated urinary tract infections and 250-500 mg twice daily for respiratory tract infections.
Patients who are hypersensitive to cefuroxime or to other cephalosporins.
Care is necessary in patients with a history of allergy.
GI disturbances, including diarrhea, nausea and vomiting have occurred in some patients receiving cefuroxime axetil. There have been rare reports of erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis.
Probenecid reduces the renal clearance of cefuroxime.
Store at temperatures not exceeding 30°C.
J01DC02 - cefuroxime ; Belongs to the class of second-generation cephalosporins. Used in the systemic treatment of infections.
FC tab 500 mg x 12's. Powd for oral susp 250 mg/5 mL x 70 mL.